Why GLP-1 weight loss drugs are catching investor attention

This week Stanford Brown CEO Vincent O'Neill meets once again with CIO Nick Ryder to discuss:

• The RBA’s widely anticipated rate hike and where to from here?
• Driving factors behind Australia’s higher-than-expected inflation numbers
• Whether geopolitical risks impact portfolio positioning?
• The potential for GLP-1 “wonder drugs” to impact different companies such as Resmed and CSL 

Music provided by: Autumn Trumpet Background Corporate by LesFM | https://lesfm.net/ Music promoted by https://www.chosic.com/free-music/all/ Creative Commons CC BY 3.0 https://creativecommons.org/licenses/by/3.0/